Slides
Page 1
Chris Lee, CEO Anna Wasyl, CFO TRISTEL PLC 2026 AUDITED RESULTS INVESTOR PRESENTATION O C T O B E R 2 0 2 6
Page 2
D I S C L A I M E R This presentation (the “Presentation”) has been prepared by Tristel plc (the “Company”) for information purposes only and may be amended without notice. It must not be copied, reproduced, distributed or passed on to any other person, or published, in whole or in part, for any purpose, without the prior written consent of the Company. It has not been approved by an authorised person for the purposes of Section 21 of the Financial Services and Markets Act 2000 and is not investment advice, an offer or an inducement to acquire securities or engage in investment activity, nor shall it form the basis of any contract or investment decision. This Presentation is directed only at persons who are: (a) existing shareholders of the Company; (b) investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the “Financial Promotion Order”); or (c) high net worth companies, unincorporated associations or trusts within the meaning of Article 49(2) of the Financial Promotion Order; or (d) persons to whom this Presentation is communicated by an FCA-authorised firm in the course of its regulated activities, where that firm has confirmed that the communication to such persons is lawful under applicable financial promotion rules (all such persons being “Relevant Persons”). This Presentation must not be acted or relied upon by persons who are not Relevant Persons. Any investment or investment activity to which this Presentation relates is available only to Relevant Persons and will only be engaged in with Relevant Persons. By receiving this Presentation, you are deemed to confirm that you are a Relevant Person. Cavendish Capital Markets Limited, which is authorised and regulated by the Financial Conduct Authority, is acting exclusively for the Company as nominated adviser and broker and will not be responsible to anyone else for providing client protections or advice in relation to this Presentation. No representation or warranty, express or implied, is or will be made by the Company, Cavendish Capital Markets Limited or any of their respective directors, officers, employees, shareholders, partners, members, agents or advisers (together, “Relevant Parties”) as to the fairness, accuracy, completeness or correctness of the information or opinions contained in this Presentation. To the fullest extent permitted by applicable law, none of the Relevant Parties accepts any responsibility or liability whatsoever for any loss arising from any use of this Presentation or its contents or otherwise arising in connection therewith. Accordingly, no reliance should be placed on the information contained in this Presentation, which does not purport to be complete and is subject to change without notice. This presentation does not constitute an offer or invitation to underwrite, subscribe for, or otherwise acquire or dispose of any Tristel shares or other securities, or of any of the businesses or assets described in the presentation, whether in the United Kingdom or any other jurisdiction, and the information contained herein cannot be relied upon as a guide to future performance. IMPORTANT – JURISDICTION-SPECIFIC DISTRIBUTION RESTRICTIONS The distribution of this Presentation in certain jurisdictions may be restricted by law. Persons into whose possession this Presentation comes should inform themselves about, and observe, any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction. In particular, this Presentation is not for distribution, directly or indirectly, in or into the United States of America (save that it may be communicated to persons that are “qualified institutional buyers” as defined in Rule 144A under the United Securities Act of 133, as amended), Australia, Canada, Japan, the Republic of South Africa or any other jurisdiction where to do so would constitute a breach of applicable law or regulation. Any forward-looking statements are based on current expectations, involve risks and uncertainties, so actual results may differ materially, and speak only as of the date of this Presentation. Forward-looking statements may be identified by the use of words such as “plans”, “expects”, “is expected to”, “scheduled”, “estimates”, “intends”, “anticipates”, “believes”, or variations of such words or phrases, or statements that certain actions, events or results “may”, “could”, “should”, “would”, “might” or “will” occur or be achieved. Such statements are based on numerous assumptions regarding the Company’s present and future business strategies and the environment in which the Company will operate, which assumptions may or may not prove correct. Prospective investors should not place undue reliance on any forward-looking statements. Except as required by law or regulation, including the AIM Rules for Companies, the Company undertakes no obligation to update them. Recipients should seek independent professional advice. MARKET ABUSE – IMPORTANT NOTICE Nothing in this presentation constitutes inside information for the purposes of the UK Market Abuse Regulation (Regulation (EU) No 596/2014 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended (“UK MAR”). The Company confirms that this Presentation has been prepared on the basis of publicly available information only. Recipients of this Presentation are reminded that the UK MAR prohibits insider dealing and the unlawful disclosure of inside information (Article 14 UK MAR) and market manipulation (Article 15 UK MAR). Nothing in this Presentation should be construed as an inducement to engage in conduct that would constitute market abuse under the UK MAR.
Page 3
3 O U R C O M P A N Y TRISTEL 2026 AUDITED RESULTS · INVESTOR PRESENTATION We are a global infection prevention company. The entire purpose of our business is to prevent the transmission of microbes from one object or person to another. We achieve our mission by applying a very powerful biocidal chemistry – chlorine dioxide – to the target environmental surface or medical device.
Page 4
4 C E O I N T R O D U C T I O N TRISTEL 2026 AUDITED RESULTS · INVESTOR PRESENTATION Chris Lee Chief Executive Officer Chris joined Tristel as CEO in August 2026, bringing 35+ years’ MedTech experience across corporate, SME and start-up companies. He has led strategic development and expansion of multiple businesses across the UK/Europe, Asia and the USA. Chris spent 18 years at Johnson & Johnson across multiple specialty segments, latterly leading the Ethicon Franchise across EMEA. Most recently he was CEO of Summit Medical Ltd, a UK-based medical device group. Skills Chris brings to the Board: – Strategic and operational leadership of fully integrated businesses – Driving growth in international markets, including the USA and Asia – Leading international teams in businesses with global growth ambitions – In-depth knowledge of global customer and distribution channels – Strong record of developing people – Public company experience in the UK and Singapore
Page 5
5 T R I S T E L B O A R D O F D I R E C T O R S TRISTEL 2026 AUDITED RESULTS · INVESTOR PRESENTATION Chris Lee Chief Executive Officer Bruno Holthof Independent Non-Executive Chair Anna Wasyl Chief Financial Officer Isabel Napper Senior Independent Non-Executive Director Tom Jenkins Independent Non-Executive Director Caroline Stephens Independent Non-Executive Director
Page 6
FINANCIAL PERFORMANCE
Page 7
* Measures adjusted for share-based payment charges, exceptional items and RDEC. 7 F I N A N C I A L H I G H L I G H T S TRISTEL 2026 AUDITED RESULTS · INVESTOR PRESENTATION +10% Turnover to a record £51.1m UK +5%, overseas +13%, Americas sales tripled +15% Adjusted* PBT to £11.7m +20% Adjusted* EBITDA to £15.7m A margin of 31% +6% Adjusted* EPS of 18.19p Reported results Profit before tax up 30% to £11.0m EBITDA up 33% to £15.0m EPS up 20% to 16.68p Cash and dividend Operating cash flow of £11.1m, up 8% Cash and short-term investments of £16.0m, debt free Final dividend of 9.23p per share to be paid in December 2026 Total dividend up 5% to 14.91p
Page 8
0% 10% 20% 30% 40% 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 - 10,000 20,000 30,000 40,000 50,000 60,000 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 Revenue £'000 Consistent Profitability - 5,000 10,000 15,000 20,000 Jun-20 Dec-20 Jun-21 Dec-21 Jun-22 Dec-22 Jun-23 Dec-23 Jun-24 Dec-24 Jun-25 Dec-25 Jun-26 Expanding Cash Generation Strong Record in Revenue Growth 10% revenue growth YoY with £4.3m coming from volume and £0.3m from price Continuous strong cash generation from operating activities, allowing for investments and progressive dividends H1 H2 Short term investments Cash and cash equivalents Cash generated from operating activities Track record in growing profitability and a commitment of adj. EBITDA above 25% COVID Committed EBITDA margin Adjusted EBITDA margin 8 K E Y I N D I C A T O R S TRISTEL 2026 AUDITED RESULTS · INVESTOR PRESENTATION
Page 9
*Adjusted PBT and EBITDA exclude share-based payment charges, exceptional items and RDEC. FY 2026 FY 2025 %Var Turnover 51.1 46.5 10% Gross profit 41.9 37.5 12% Gross profit margin % 82% 81% Admin and distribution expenses (26.8) (24.9) 8% Depreciation, Amortisation and Impairments (3.5) (2.4) 48% Net finance income 0.1 0.0 600% Adjusted Profit before tax (PBT)* 11.7 10.1 15% Adjusted PBT margin %* 23% 22% Share Based Payments, Exceptionals and RDEC (0.7) (1.7) (59%) PBT 11.0 8.4 30% Tax (3.0) (1.8) 69% Profit 8.0 6.6 20% Adjusted EBITDA* 15.7 13.0 20% Adjusted EBITDA margin %* 31% 28% • 94% of YoY revenue growth came from volume (£4.3m), with £0.3m from price • In-house wipe manufacturing completed, lifting gross margin to 82% • Staff costs up 12% to £18.8m as average headcount rose from 265 to 281 mostly in commercial teams • Depreciation, amortisation and impairments include a £0.8m impairment of Surfaces intangibles • 15% increase YoY in adjusted PBT • Adjusted EBITDA margin of 31%, comfortably above target of 25% 9 I N C O M E S T A T E M E N T ( £ M ) TRISTEL 2026 AUDITED RESULTS · INVESTOR PRESENTATION
Page 10
Progressive Dividend Robust ROCE Healthy Net Working Capital NWC fell from 16.0% to 15.2% of revenue over two years, as revenue grew 22% against 16% for NWC, freeing cash for growth and investment Net working capital 14% 15% 16% 17% - 20,000 40,000 60,000 Jun-24 Dec-24 Jun-25 Dec-25 Jun-26 Revenues past 12 months NWC/Revenue 12 months Healthy ROCE reflecting capital efficiency, operational performance, strengthening profitability and long-term value creation 0 10 20 FY13 FY14 FY15 FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25 FY26 Pence per share Final Interim Special Progressive dividend reaching 14.91 p 0% 10% 20% 30% Jun-24 Dec-24 Jun-25 Dec-25 Jun-26 ROCE (annualised) ROCE (annualised) [excluding exceptionals] 10 B A L A N C E S H E E T K P I S TRISTEL 2026 AUDITED RESULTS · INVESTOR PRESENTATION
Page 11
11 B A L A N C E S H E E T ( £ M ) TRISTEL 2026 AUDITED RESULTS · INVESTOR PRESENTATION • Debt free with equity backed growth • 25% growth in cash to a record £16.0m (June 2025 £12.8m) • Total liabilities remain modest at £12.6m • Ample financial capacity to support planned investment and growth initiatives 30-Jun-26 31-Dec-25 30-Jun-25 31-Dec-24 30-Jun-24 Tangible assets 8.5 8.7 9.0 9.0 8.9 Intangible assets 8.7 9.5 10.0 9.8 9.9 Other non-current assets 0.6 0.8 0.2 0.8 0.6 Total non-current assets 17.8 19.0 19.2 19.6 19.4 Other current assets 14.5 13.1 13.3 11.5 12.9 Cash 16.0 13.3 12.8 11.7 11.8 Total current assets 30.5 26.4 26.1 23.2 24.7 Total assets 48.3 45.4 45.3 42.8 44.1 Equity 16.6 15.9 15.8 15.8 15.4 Other reserves 1.5 1.6 1.4 1.2 1.6 Retained earnings 17.6 16.1 15.8 14.5 15.4 Total equity 35.7 33.6 33.0 31.5 32.4 Lease liabilities 4.6 4.7 4.7 4.9 4.8 Other non-current liabilities 0.3 0.7 0.4 0.6 0.3 Total non-current liabilities 4.9 5.4 5.1 5.5 5.1 Lease liabilities 1.2 1.1 1.1 1.0 1.0 Other current liabilities 6.4 5.3 6.1 4.8 5.6 Total current liabilities 7.6 6.4 7.2 5.8 6.6 Total liabilities 12.6 11.8 12.3 11.3 11.7 Total equity and liabilities 48.3 45.4 45.3 42.8 44.1
Page 12
*includes £271k royalties • EMEA up 15%, the largest contributor to growth • UK up 5%, MDD growing at 8%, SD at 21% and legacy declining by 63% • APAC broadly stable as device growth offset lower non-core sales • Americas up 200% as ULT gained traction and OPH launched UK £18.2m +5% Americas £0.8m* +200% EMEA £24.1m +15% APAC £8.0m +1% 12 1 0 % G L O B A L R E V E N U E G R O W T H , R E A C H I N G £ 5 1 . 1 M TRISTEL 2026 AUDITED RESULTS · INVESTOR PRESENTATION
Page 13
FY25 FY26 Growth £'000 £'000 Direct USA Product Sale 33 340 930% Royalty* 109 271 149% Total US 142 611 331% Distributor Sales Canada & Chile 123 189 54% Americas Total 265 800 202% *Includes royalty payments associated with sales in Canada of £5K in FY26 (£6k FY25) 13 T R I S T E L R E V E N U E S I N A M E R I C A S ( £ K ) TRISTEL 2026 AUDITED RESULTS · INVESTOR PRESENTATION
Page 14
USA PERFORMANCE
Page 15
5 27 48 86 153 203 32 173 306 548 981 1,301 - 200 400 600 800 1,000 1,200 1,400 H1 FY24 H2 FY24 H1 FY25 H2 FY25 H1 FY26 H2 FY26 Tristel ULT estimated sales and royalties in the US market ($’000) Royalty Estimated In Market Sales • Royalty income $355k • 736,000 procedures vs 300,000 procedures in 2025 • Growth drivers: – uplift in existing user utilisation – 190 new user sites added in the last 6 months since March report – 275 open opportunities in a pipeline with 175 in different stages of completing value analysis and in trials and implementation training 15 US T R I S T E L U L T S A L E S TRISTEL 2026 AUDITED RESULTS · INVESTOR PRESENTATION
Page 16
16 T R I S T E L U L T S U C C E S S S T O R I E S A N D T E S T I M O N I A L S TRISTEL 2026 AUDITED RESULTS · INVESTOR PRESENTATION “Being able to perform the process at point-of-care with essentially a two- minute wait time, allows the probe to go right back on the machine so staff can move directly to the next patient.” Children’s Health Ran pilot trials in interventional radiology and echocardiology, and delivered a 2-minute bedside turnaround with no paper logs. Traci Major, MHA, CSPM, CSPDT, CER Director Perioperative Services Sterile Processing, HLD, and Sterilization “It’s convenient, easy, more cost effective, and reduced our probe down time. Since switching to Tristel, we haven’t sent in any probes to be repaired due to HLD processing.” Mercy Hospital Rolled ClO2 out across 29 Mercy locations in 4 states, validating the method through real-world data and demonstrating faster room turnover and streamlined documentation. Jennifer Griest, BSN, RN Infection Prevention Specialist “Our recent TJC audit went great, they (Joint Commission) love Tristel ULT and were very excited that we were using it… Rave reviews for Tristel ULT throughout the enterprise and TJC!” University of Iowa Health Care Transitioned from VHP to ClO2 achieving a “gold stars all around” result and eliminating approximately $60K/year in maintenance costs. Nikki Robertson, MHA, RDMS, RVT Ultrasound Services Manager
Page 17
US T R I S T E L O P H S A L E S TRISTEL 2026 AUDITED RESULTS · INVESTOR PRESENTATION • FY26 revenues at $260k exceeding initial expectations • 111,000 customer procedures performed • 73 accounts using at year end • 304 open opportunities – 207 at trial and evaluating, with 97 engaged • Gross margin developing in line with Group targets • Strong partners in Advancing Eyecare & Keeler88 172 72.6 145.2 - 40 80 120 160 200 H1 FY26 H2 FY26 Tristel OPH revenue in the US market FY26 by half-year ($’000) Tristel Revenue Estimated In Market Sales Adopted by America’s leading eye care providers: Hospitals: Cleveland Clinic Manhattan Eye and Ear Eye Institutes: UCLA Stein and Doheny, Penn Medicine Scheie, Vanderbilt Children’s Hospitals: Boston, Colorado Stanford, Cincinnati
Page 18
18 U S O P H P R O G R E S S – A Y E A R A G O TRISTEL 2026 AUDITED RESULTS · INVESTOR PRESENTATION Pipeline Live users
Page 19
• Recruitment in Midwest and Westcoast and Marketing completed • Developing distribution partnerships and about to sign an established supplier into VA and government hospitals • Strategic partnerships with ophthalmic device manufacturers Lumibird, NeoLight, Natus • Collaboration with all device manufacturers on IFU inclusion of Tristel OPH • Multi centre study (7 sites) to create best practice recommendations for reprocessing Pipeline Live users 19 U S O P H P R O G R E S S - T O D A Y TRISTEL 2026 AUDITED RESULTS · INVESTOR PRESENTATION
Page 20
20 T R I S T E L O P H S U C C E S S S T O R I E S A N D T E S T I M O N I A L S TRISTEL 2026 AUDITED RESULTS · INVESTOR PRESENTATION “Before adopting Tristel OPH, we relied on low-level disinfection for our ophthalmic probes due to lack of practical high-level disinfection options. Tristel OPH has completely changed that. It has enabled us to implement true high-level disinfection with minimal disruption to our workflow. The system is fast, reliable, and easy for our team to use; it gives us full confidence that every probe entering the OR meets the highest standards of safety and compliance. Tristel OPH has strengthened our infection-control practices and elevated the standard of care we provide to our patients.” Rhonda Dunklin Patient Care Coordinator, Surgical Services, Willis Knighton Health South “Tristel OPH has been straightforward for our team to adopt. The onboarding process was simple, and our staff quickly became fully competent and confident in using the system. It has already delivered meaningful improvements to our workflow and overall efficiency. We are loving the product!” Allyson Kelly Manager, Ophthalmology, MetroHealth Main Campus
Page 21
PROGRESS MADE
Page 22
22 E V I D E N C E A S A C O M P E T I T I V E A D V A N T A G E TRISTEL 2026 AUDITED RESULTS · INVESTOR PRESENTATION E D U C A T I N G T H E M A R K E T Chlorine dioxide outperforms, but it needs explaining. As competitors position look- alike products, buyers who understand the chemistry are our strongest defence. D E L I V E R E D July 2026 launch 8 regional sites live 15+ published studies 30+ educational articles E A R L Y S I G N A L S 65% UK launch email open rate +47% uplift in UK page views N E X T Roll-out to further regions Resource packs for hospital IPC teams Engagement tracked to pipeline
Page 23
T R I S T E L 2 0 2 6 A U D I T E D R E S U L T S · I N V E S T O R P R E S E N T A T I O N A R E C U R R I N G P R O B L E M I N H O S P I T A L S B B C N E W S S E P 2 0 2 1 Boy's infection 'came from hospital drains' Scottish Hospitals Inquiry hears from family of 10-year-old cancer patient B B C N E W S A U G 2 0 2 4 Staff 'anxious' for child cancer patients Inquiry told of black, slimy grime from drains reaching sinks on cancer wards L O C A L N E W S O C T 2 0 2 5 Wexham Park rebuilds ICU to stop superbug Sinks and drains ripped out after CPE outbreak was linked to hospital drains 22,000+ drug-resistant CPO cases reported in England, Oct 2020 – Mar 2025 100–1000x harder to kill bacteria once protected inside a drain biofilm W H Y T R I S T E L W I N S The gap Standard drain products (chlorine, peracetic acid) don't reliably penetrate established biofilm. Our chemistry Chlorine dioxide is a small gas molecule that diffuses through biofilm where others can't. Fits the routine Foam coats the whole drain, U- bend to cover, in a 10-minute contact time. Sources: BBC News; Maidenhead Advertiser; UKHSA, Carbapenemase-producing Gram-negative organisms in England, quarterly update Q1 2025; Maillard & Centeleghe, 2023. 23 H O S P I T A L D R A I N S : A S E R I O U S , U N S O L V E D I N F E C T I O N R I S K
Page 24
T R I S T E L 2 0 2 6 A U D I T E D R E S U L T S · I N V E S T O R P R E S E N T A T I O N W H A T I P C L E A D E R S S A Y “There has long been a gap for a drain disinfection product that is both effective against biofilm and practical for routine day-to-day use. In my view, Unifoam addresses that unmet need, not only for the NHS but also for healthcare settings internationally.” Dr Phil Norville, BSc MSc PhD CEO and Co-founder IPC Partners “Sinks and drains have become one of the most persistent challenges we face in infection prevention… IPC teams have been asking for a drain disinfection solution that is effective against biofilm and straightforward for frontline staff to use consistently.” Jincy Jerry Director of IPC, NHS Ayrshire & Arran R O U T E T O M A R K E T Sept 2025 Unmet need identified with IPC teams Sep 2026 IPS soft launch: 14 Trusts request trials Oct 2026 Awareness campaign; trials under way Jan 2027 Phase 1 market launch Next Further markets to follow 24 B A C K E D B Y I P C L E A D E R S
Page 25
T R I S T E L 2 0 2 6 A U D I T E D R E S U L T S · I N V E S T O R P R E S E N T A T I O N T R A C E A B I L I T Y I S S T A N D A R D . 3 T G O E S F U R T H E R . Training Free Traceability Paid Pro Paid Enhanced reporting Multi-site dashboards + admin Medical device lifecycle tracking Department controls Audit checklists Staff trained and certified W H E R E M O S T A L T E R N A T I V E S S T O P Digital cycle log Mobile app Staff scan the device, the disinfectant and themselves at the point of care. Each cycle is logged as it happens. Web platform IPC leads see every cycle, device and trained user across departments and sites, with audit-ready reports. A virtual member of the IPC team: that daily reliance makes Tristel very hard to replace. W H A T 3 T I S W H A T E X I S T I N G C U S T O M E R S S A Y A B O U T U S I N G 3 T Nikki Robertson Ultrasound Services Manager University of IOWA Health Centre “3T is a really great way for us to standardise the process no matter who is using the Tristel ULT product. Joint commission were so impressed - gold stars all around” Traci Major Director Perioperative Services Sterile Processing, HLD, and Sterilization Children’s Health “Tristel ULT and 3T streamlined the paperwork process and simplified the workflow for us…” 25 3 T S O F T W A R E . S T R E N G T H E N I N G O U R P O S I T I O N
Page 26
T R I S T E L 2 0 2 6 A U D I T E D R E S U L T S · I N V E S T O R P R E S E N T A T I O N JUL 2025 Tristel commit to commercialise 3T by end of FY25/26 JUN 2026 Three tiers launched on schedule: Training, Traceability and Pro TODAY Priced in the UK, US, Australia and NZ, home to 81% of active organisations S C A L E O F T H E P L A T F O R M 48,800 staff training certifications since July 2025 c.250,000 decontamination cycles logged in the last 12 months 272 organisations actively logging cycles, in 19 countries 100+ Active prospects in CRM globally for 3T traceability W H Y 3 T W I N S • Paid tiers signal value Charging for Traceability and Pro positions 3T as a clinical tool, not a free add-on. • Daily use builds reliance Pro tools are used every day at the point of care, so 3T becomes part of the IPC team’s routine. • Subscriptions anchor chemistry Multi-year 3T contracts secure Tristel disinfectant purchases for the long term alongside a compliance platform they rely on. • Hard for alternatives to match Most competitors stop at a digital cycle log; 3T adds training, device tracking, audit and multi-site controls. Cycles: 12 months to 17 August 2026. Active organisations: logging cycles in the last 90 days. 26 T H E N E X T G E N E R A T I O N : C O M M E R C I A L I S A T I O N
Page 27
OUTLOOK
Page 28
28 G L O B A L M A R K E T T R E N D S & C L I N I C A L P R O G R E S S TRISTEL 2026 AUDITED RESULTS · INVESTOR PRESENTATION 1. Ultrasound is moving to the point of care, beyond the imaging department and central reprocessing 2. More ultrasound-guided procedures mean more probes needing fast, compliant HLD at the bedside 3. Guidelines are moving our way: AIUM now recognises chlorine dioxide for HLD and ACEP is updating its guidance 4. Infection risk stays high: 1 in 6 infections are antibiotic resistant (WHO), keeping compliance in focus 5. Tight budgets favour low-capital HLD at the point of care +3 clinically relevant guidelines updated to include chlorine dioxide. • SMFM, July 2026. Tristel ULT named as HLD with proven efficacy against HPV. • AIUM, 2025 revision. ClO2 added to approved methods for HLD of Ultrasound probes. • ACEP, October 2025. ClO2 added to approved methods for HLD of Ultrasound probes. +20 device manufacturers confirmed or extended compatibility with Tristel products in FY25/26, including full probe portfolios from three ultrasound OEMs
Page 29
29 O U T L O O K TRISTEL 2026 AUDITED RESULTS · INVESTOR PRESENTATION • Accelerating investment plans in the US, where ULT and OPH remain significant growth opportunities over the coming years • Assessing market attractiveness to support geographical expansion for medium to long term growth • Further enhancing Tristel’s reputation through clinical leadership and KOL engagement • Focus on commercial execution to capitalize on targeted opportunities in current markets: – increased customer share of wallet through expanding use of Tristel’s portfolio – growth in penetration levels in line with internal benchmarks - ~£60 m additional medical device disinfection revenue potential if our current markets reach benchmark relevant to their maturity levels (ranging from 5 to 50 procedures per 1,000 inhabitants with the most mature markets held flat) • Unifoam and 3T Pro product launches creating new revenue streams • Robust R&D pipeline to fuel future growth
Page 30
30 O U R 2 0 2 5– 2 0 3 0 F I N A N C I A L C O M M I T M E N T S TRISTEL 2026 AUDITED RESULTS · INVESTOR PRESENTATION * Excluding Share Based Payments Metric Revenue Growth EBITDA* Margin Dividend Policy Target Double Digit Annually ≥25% Annually Progressive YoY Growth Timeframe FY25–FY30 Every Year Ongoing
Page 31
31 S U M M A R Y TRISTEL 2026 AUDITED RESULTS · INVESTOR PRESENTATION Strategic focus remains the same 01 Expanding Tristel’s portfolio across underpenetrated attractive markets 02 Investing in accelerated adoption and commercial execution 03 Expanding global clinical leadership and brand recognition with the IPC ● Results in line with expectations; business remains firmly on track to meet its financial targets ● Continued commitment to US growth and accelerated investments in the market ● Increased penetration across selected existing markets alongside new product launches and digital offering will be significant growth drivers ● Tristel remains well-positioned to deliver long-term shareholder value
Page 32
Q&A
Page 33
APPENDIX
Page 34
FY 2026 FY 2025 £’000 £’000 Turnover 51,117 46,462 Cost of sales excluding depreciation (8,581) (8,524) Depreciation included within cost of sales (610) (479) Gross profit Gross margin % 41,926 82% 37,459 81% Distribution costs (840) (344) Administrative expenses less other operating income (25,833) (24,601) Share based payments (605) (371) Exceptional items (274) (1,358) Depreciation, amortisation and impairments (3,530) (2,388) Operating profit 10,844 8,397 Finance income 373 278 Finance costs (240) (259) Pre-tax profit 10,977 8,416 Tax charge (2,993) (1,776) Profit after tax 7,984 6,640 Basic EPS – pence 16.68 13.92 Diluted EPS – pence 16.57 13.83 34 A P P E N D I X – I N C O M E S T A T E M E N T TRISTEL 2026 AUDITED RESULTS · INVESTOR PRESENTATION
Page 35
30.06.2026 30.06.2025 Non-current assets £’000 £’000 Goodwill 4,926 4,971 Intangible assets 3,780 5,016 Property, plant and equipment 3,031 3,431 Right of use assets 5,513 5,553 Deferred tax 550 187 17,800 19,158 Current assets Inventories 4,342 4,642 Trade and other receivables 9,835 8,463 Income tax receivable 287 227 Cash and short-term investments 16,004 12,844 30,468 26,176 Total assets 48,268 45,334 35 A P P E N D I X – B A L A N C E S H E E T TRISTEL 2026 AUDITED RESULTS · INVESTOR PRESENTATION
Page 36
30.06.2026 30.06.2025 Capital and reserves £’000 £’000 Share capital 480 478 Share premium account 16,115 15,310 Merger reserve 2,205 2,205 Foreign exchange reserve (679) (798) Retained earnings 17,594 15,796 Total equity 35,715 32,991 Non-current liabilities Lease liabilities 4,617 4,738 Deferred tax liabilities 136 193 Provision 176 147 4,929 5,078 Current liabilities Lease liabilities 1,241 1,139 Trade and other payables 6,383 6,072 Income tax liability - 54 Total liabilities 12,553 12,343 Total equity and liabilities 48,268 45,334 36 A P P E N D I X – B A L A N C E S H E E T … C O N T I N U E D TRISTEL 2026 AUDITED RESULTS · INVESTOR PRESENTATION
Page 37
Year ended 30.06.2026 Year ended 30.06.2025 Cash flows from operating activities Profit before tax for the year 10,977 8,416 Adjustments to cashflows for non-cash items Depreciation and amortisation 3,239 2,800 Loss on disposal and impairment of assets 966 134 Net finance income (133) (19) Increase in restoration provision (24) - Share based payments 605 371 15,630 11,702 Working capital adjustments Decrease in inventories 300 39 Increase in trade and other receivables (1,372) (939) Increase in trade and other payables 311 590 Increase in provisions 29 147 Lease interest paid (240) (259) 14,658 11,280 Cash generated from operations excluding exceptional items 14,932 12,638 Cash outflow from operations of exceptionals (274) (1,358) Income taxes paid (3,528) (964) Net cash flow from operating activities 11,130 10,316 37 A P P E N D I X – C A S H F L O W S T A T E M E N T TRISTEL 2026 AUDITED RESULTS · INVESTOR PRESENTATION
Page 38
Year ended 30.06.2026 Year ended 30.06.2025 Cash flows from investing activities Interest received 373 278 Purchases of property plant and equipment (683) (857) Acquisition of intangible assets (580) (1,125) Cash deposit to short-term investments (7,230) (11,200) Receipts from short-term investments maturing in the year 10,430 12,650 Net cash from/(used in) investing activities 2,310 (254) Cash flows from financing activities Share issues 807 379 Payments to lease creditors (1,194) (1,026) Dividends paid (6,791) (6,658) Net cash flows used in financing activities (7,178) (7,305) Net increase in cash and cash equivalents 6,262 2,757 Cash and cash equivalents at the beginning of the year 8,644 6,139 Effect of exchange-rate fluctuations on cash held 98 (252) Cash and cash equivalents at the end of the year 15,004 8,644 Enterprise free cash flow 9,867 8,334 38 A P P E N D I X – C A S H F L O W S T A T E M E N T … C O N T I N U E D TRISTEL 2026 AUDITED RESULTS · INVESTOR PRESENTATION